Chemotherapy is a type of systemic anti-cancer therapy (SACT). Chemotherapy information sheets provide details about individual chemotherapy treatments.
We also have a number of immunotherapy information sheets. Immunotherapy is a treatment which uses your immune system to fight cancer. It works by helping the immune system recognise and attack cancer cells. Some types of immunotherapy are also called targeted treatments or biological therapies.
Your doctor will discuss your treatment with you when you come to The Christie.
Each information sheet includes:
- name of drugs
- the way the drugs are given, for example, injection or via a drip
- treatment cycle (which days or weeks you have treatment and how long treatment lasts)
- side effects and how to cope
- contact numbers
Click on the name of the treatment you wish to view.
E
Epirubicin [PDF, 103 KB]
You can also read this information in an accessible format on our Epirubicin page.
Epirubicin and cyclophosphamide [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin and cyclophosphamide (EC) page.
Epirubicin then cyclophosphamide then docetaxel, trastuzumab (EC-TH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin then cyclophosphamide then docetaxel, trastuzumab (EC-TH) page.
Epirubicin then cyclophosphamide, methotrexate and fluorouracil (Epi-CMF) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin then cyclophosphamide, methotrexate and fluorouracil (Epi-CMF) page.
Epirubicin, cyclophosphamide then docetaxel (EC-T) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel (EC-T) page.
Epirubicin, cyclophosphamide then docetaxel, pertuzumab and trastuzumab (EC-TPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel, pertuzumab and trastuzumab (EC-TPH) page.
Epirubicin, cyclophosphamide then docetaxel, trastuzumab (EC-TH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then docetaxel, trastuzumab (EC-TH) page.
Epirubicin, cyclophosphamide then paclitaxel (EC-P or P-EC) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin-cyclophosphamide then paclitaxel (EC-P or P-EC) page.
Epirubicin, cyclophosphamide then paclitaxel and trastuzumab (EC-PH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then paclitaxel and trastuzumab (EC-PH) page.
Epirubicin, cyclophosphamide then paclitaxel, pertuzumab and trastuzumab (EC-PPH) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin, cyclophosphamide then paclitaxel, pertuzumab and trastuzumab (EC-PPH) page.
Epirubicin-cyclophosphamide then carboplatin-paclitaxel (EC-PC) or (PC-EC) [PDF, 104 KB]
You can also read this information in an accessible format on our Epirubicin-cyclophosphamide then carboplatin-paclitaxel (EC-PC) or (PC-EC) page.
Eribulin [PDF, 103 KB]
You can also read this information in an accessible format on our Eribulin page.
Everolimus (Breast) [PDF, 104 KB]
You can also read this information in an accessible format on our Everolimus page.
Exemestane [PDF, 167 KB]
You can also read this information in an accessible format on our Exemestane page.